Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy

References

• Loncaster JA, Carrington BM, Sykes JR, Jones AP, Todd SM, Cooper R, et al. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002; 54: 759–67
   PubMed Web of Science ®Google Scholar
• Gong QY, Brunt JN, Romaniuk CS, Oakley JP, Tan LT, Roberts N, et al. Contrast enhanced dynamic MRI of cervical carcinoma during radiotherapy: Early prediction of tumour regression rate. Br J Radiol 1999; 72: 1177–84
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J. Basic clinical radiobiology. 2nd ed. London: Arnold; 1997. p 132–141.
   Google Scholar
• Bentzen SM. Radiation therapy: Intensity modulated, image guided, biologically optimized and evidence based. Radiother Oncol 2005; 77: 227–30
   PubMed Web of Science ®Google Scholar
• Malinen E, Søvik Å, Hristov D, Bruland ØS, Olsen DR. Adapting radiotherapy to hypoxic tumours. Phys Med Biol 2006; 51: 4903–21
   PubMed Web of Science ®Google Scholar
• Tomé WA, Fowler JF. Selective boosting of tumor subvolumes. Int J Radiat Oncol Biol Phys 2000; 48: 593–9
   PubMed Web of Science ®Google Scholar
• Wang JZ, Li XA. Impact of tumor repopulation on radiotherapy planning. Int J Radiat Oncol Biol Phys 2005; 61: 220–7
   PubMed Web of Science ®Google Scholar
• Tomé WA, Fowler JF. On the inclusion of proliferation in tumour control probability calculations for inhomogeneously irradiated tumours. Phys Med Biol 2003; 48: N261–N268
   PubMedGoogle Scholar
• Søvik Å, Malinen E, Skogmo HK, Bentzen SM, Bruland ØS, Olsen DR. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int J Radiat Oncol Biol Phys 2007; 68: 1496–504
   PubMed Web of Science ®Google Scholar
• Lyng H, Vorren AO, Sundfør K, Taksdal I, Lien HH, Kaalhus A, et al. Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging. J Magn Reson Imaging 2001; 14: 750–6
   PubMed Web of Science ®Google Scholar
• , UICC (International Union Against Cancer)Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind C. TNM-Atlas. 4th ed. Berlin: Springer Verlag; 1997. p 309–314.
   Google Scholar
• Haider MA, Sitartchouk I, Roberts TPL, Fyles A, Hashmi AT, Milosevic M. Correlations between dynamic contrast-enhanced magnetic resonance imaging-derived measures of tumor microvasculature and interstitial fluid pressure in patients with cervical cancer. J Magn Reson Imaging 2007; 25: 153–9
   PubMed Web of Science ®Google Scholar
• Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999; 10: 254–9
   PubMed Web of Science ®Google Scholar
• Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004; 10: 3650–7
   PubMed Web of Science ®Google Scholar
• Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: Standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223–32
   PubMed Web of Science ®Google Scholar
• Walker-Samuel S, Leach MO, Collins DJ. Evaluation of response to treatment using DCE-MRI: The relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis. Phys Med Biol 2006; 51: 3593–602
   PubMed Web of Science ®Google Scholar
• Yankeelov TE, Luci JJ, Lepage M, Li R, Debusk L, Lin PC, et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: A reference region model. Magn Reson Imaging 2005; 23: 519–29
   PubMed Web of Science ®Google Scholar
• Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007; 8: 63–74
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Baba T, Baba Y, Nishimura R, Ikeda S, Takahashi M, et al. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: Pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology 2000; 216: 803–9
   PubMed Web of Science ®Google Scholar
• Robinson P, Collins CD, Ryder WDJ, Carrington BM, Hutchinson CE, Bell D, et al. Relationship of MRI and clinical staging to outcome in invasive bladder cancer treated by radiotherapy. Clin Radiol 2000; 55: 301–6
   PubMedGoogle Scholar
• Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008; 70: 235–42
   PubMed Web of Science ®Google Scholar
• Muren LP, Smaaland R, Dahl O. Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiother Oncol 2003; 69: 291–304
   PubMed Web of Science ®Google Scholar
• Redpath AT, Muren LP. CT-guided intensity-modulated radiotherapy for bladder cancer: Isocentre shifts, margins and their impact on target dose. Radiother Oncol 2006; 81: 276–83
   PubMed Web of Science ®Google Scholar